Alnylam Pharmaceu…
USUSDAlnylam Pharmaceuticals Inc (US:ALNY) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- alnylam.com
- Взаимодействие с инвесторами
- investors.alnylam.com/press-releases
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Штаб-квартира
- Cambridge, United States
- Генеральный директор
- Dr. Yvonne L. Greenstreet M.B.A., M.D.
- Сотрудники
- 2 500
- Основана
- 2002
- Акций в обращении
- 133.81 млн на 2026-07-24
- Свободное обращение
- 133.24 млн
- Рыночная капитализация
- 34.17 млрд USD
- Инсайдеры
- 0.18%
- Институциональные инвесторы
- 101.67%
- Отрасль (SIC)
- Pharmaceutical Preparations
- ISIN
- US02043Q1076
- LEI
- 529900S3ZI14OWRJII50
Описание
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 09.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости этой недели
За последнюю неделю новостей нет. Последняя новость: 29.09.2026.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| FMR, LLC | 11.23% | 15.02 млн | 2026-06-30 |
| Capital World Investors | 8.33% | 11.14 млн | 2026-06-30 |
| Blackrock Inc. | 8.15% | 10.91 млн | 2026-06-30 |
| Capital Research Global… | 7.29% | 9.75 млн | 2026-06-30 |
| Growth Fund of America | 5.7% | 7.62 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.89% | 6.54 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.51% | 6.03 млн | 2026-06-30 |
| T. Rowe Price Investment… | 4.22% | 5.64 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 4.24 млн | 2026-06-30 |
| Amcap Fund | 3.07% | 4.1 млн | 2026-06-30 |
| Invesco Ltd. | 2.81% | 3.75 млн | 2026-06-30 |
| State Street Corporation | 2.66% | 3.56 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.16% | 2.89 млн | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 2.87 млн | 2026-08-31 |
| JPMORGAN CHASE & CO | 2% | 2.68 млн | 2026-06-30 |
| Fidelity Securities Fund… | 1.6% | 2.14 млн | 2026-07-31 |
| T. ROWE PRICE CAPITAL AP… | 1.52% | 2.03 млн | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 1.25% | 1.67 млн | 2026-04-30 |
| VANGUARD INDEX FUNDS-Van… | 1.21% | 1.62 млн | 2026-06-30 |
| Investment Co of America | 1.21% | 1.61 млн | 2026-06-30 |
| SHARP PHILLIP A (Directo… | ≈0.2% | 266 899 | 2025-01-23 |
| GREENSTREET YVONNE L (Ch… | ≈0.07% | 96 209 | 2026-09-18 |
| POULTON JEFFREY V (Chief… | ≈0.05% | 61 862 | 2026-03-04 |
| TANGULER TOLGA (Officer) | ≈0.03% | 34 297 | 2026-03-04 |
| PYOTT DAVID E I (Directo… | ≈0.02% | 29 482 | 2026-06-01 |
| SCHULMAN AMY W. (Directo… | ≈0.02% | 24 049 | 2026-05-20 |
| FITZGERALD KEVIN JOSEPH… | ≈0.02% | 21 106 | 2026-03-05 |
| BONNEY MICHAEL W (Direct… | ≈0.02% | 20 804 | 2025-08-18 |
| GARG PUSHKAL (Officer) | ≈0.01% | 19 374 | 2026-03-05 |
| SUPRAN BRYAN (Officer) | ≈0.01% | 14 565 | 2026-03-02 |
